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Article abstract-The presence of extrapyramidal signs or psychosis may indicate greater disability in patients with probable 
Alzheimer's disease. We evaluated the ability of these signs, noted at a patient's first visit, to predict one of two specific clinical 
endpoints: (1) a preselected score on the modified Mini-Mental State examination (cognitive endpoint), and (2) a preselected 
score on the Blessed Dementia Rating Scale (functional endpoint). Sixty-five patients were followed either until they reached the 
endpoints or to the end of the study period. Survivorship curves were drawn to predict the distribution of time to onset of an 
endpoint in patients with and without the clinical signs. Time to reach the cognitive endpoint was shorter for patients with 
extrapyramidal signs or psychosis compared with those without these signs and symptoms. These clinical signs did not predict 
the functional endpoint. We conclude that extrapyramidal signs and psychosis may be useful predictors of intellectual decline in 
Alzheimer's disease. 
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Y. Stern, PhD; R. Mayeux, MD; M. Sano, PhD; W.A. Hauser, MD; and T. Bush, PhD 
It is difficult to predict when an individual patient with 
Alzheimer's disease will reach a critical stage, such as 
inability to perform simple daily activities, because the 
rate of progression varies. The clinician should be able 
to provide the patient and family with a reliable predic-
tion of the course of the disease but this is not now 
possible. 
We and others found that certain clinical signs in 
Alzheimer's disease may indicate more severe dis-
ease.1·4 Patients with myoclonus, extrapyramidal signs, 
or psychosis are more functionally and intellectually 
impaired.1-3 
We evaluated the ability of these clinical signs, when 
noted at a patient's first evaluation, to predict when the 
patient would reach a specific clinical endpoint. We 
chose two endpoints: (1) impairment of intellect, or (2) 
functional impairment in ability to perform activities of 
daily living. 
Methods. Subjects. Sixty-five patients with probable 
Alzheimer's disease (pAD), followed for up to 7.1 years 
(mean 2.8 ± 1.6), had mean age at onset of 63.8 ( ± 9.5), 
and mean years of education of 12.9 ( ± 3. 7). There were 
29 men and 36 women. Many of these patients were 
included in a previous study,1 but they have now been 
followed for a longer time, and 15 other patients have 
been added. All met DSM-III criteria for primary de-
generative dementia' and NINCDS-ADRDA criteria 
for "probable" Alzheimer's disease.6 All patients were 
followed for at least 6 months. We excluded patients 
with a history of affective disorder within 1 year of onset 
of intellectual decline; Parkinson's disease; history or 
evidence of stroke or Hachinski Ischemic score of 5 or 
more7; history or clinical evidence of cancer, or of car-
diac, hepatic, pulmonary, or renal disease; history of 
anoxia or metabolic-toxic encephalopathy; or seizures 
preceding onset of dementia. 
Procedure. All patients were evaluated at least twice, 
with a minimum interval of 6 months between evalua-
tions. Each evaluation consisted of standardized neu-
rologic, neuropsychological, and psychiatric examina-
tions. Historical information was collected at the first 
evaluation. 
Neurologic assessment. The presence of extra-
pyramidal symptoms, including tremor, rigidity, brady-
kinesia, gait, postural change and facial appearance, 
was determined and their severity rated on a 0 to 4 scale 
(0 ~ none, 4 ~ greatest severity) using an abbreviated 
version of the Columbia University Parkinson's Dis-
ease Evaluation. 8 The reliability of this scale has been 
established.9 Myoclonus and other dyskinesias were 
noted and rated on a similar scale. All medications were 
recorded. If the patient took any medication that might 
have caused extrapyramidal signs, these were consid-
ered to be drug-induced. 
Capacity for independence in activities of daily life 
was rated on part 1 of the Blessed Dementia Rating 
Scale (BDRS).10 Scores on this scale increase as func-
tional ability decreases. 
At the first visit, the patients and reliable informants 
were interviewed to determine the date at which the 
patient first met criteria for the diagnosis ofpAD. The 
reliability of our onset assessments was confirmed using 
standardized interview techniques." 
Neuropsychological assessment. General intellectual 
function was measured by a modified version of the 
Mini-Mental State Examination (mMMS).12•13 Maxi-
mum score is 57; a decrease in score is indicative of a 
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Table. Mean mMMS and BDRS scores of patients 
with and without clinical signs at their first visit 
mMMS BDRS 
Group Mean SD Mean SD 
No extrapyramidal signs 31.9 14.7 8.1 4.4 
Extrapyramidal signs 20.8 13.9* 10.8 4.4* 
No psychosis 29.9 15.9 8.7 4.7 
Psychosis 19.7 11.5* 10.6 3.7 
No myoclonus 28.1 15.2 9.1 4.6 
Myoclonus 13.3 18.2* 10.6 3.7 
* t-test comparison of group means significant at p < 0.05. 
decline in intellectual function. The mMMS correlates 
well with the original MMS and with more detailed 
neuropsychological examinations.14 
Psychiatric assessment. All subjects and available 
family members or informants were interviewed in a 
semi-structured fashion to assess the presence of psy-
chiatric symptoms, using the DSM-III as a guideline. 
The presence of persistent hallucinations, illusions, or 
delusions was sufficient to rate a patient as having 
psychosis. 
Determination of endpoints. DSM-III criteria for 
primary degenerative dementia require both cognitive 
change, including primary and other intellectual func-
tions, and functional change, defined as the inability to 
perform social or occupational function. Previously, we 
found a correlation between the mMMS and the BDRS 
(r ~ ~o.5,p < 0.05).1 This suggests that although the 
spheres of behavior that these two tests measure are 
related, there are aspects of behavior that each de-
scribes uniquely and that do not co-vary. For this rea-
son we chose to include both cognitive and functional 
endpoints. 
The point at which the patient reached an mMMS 
score of less than 20 was defined as the cognitive end-
point. This score indicates poor performance on assess-
ments of memory, orientation, language, and cal-
culation. Reaching a BDRS score of greater than 15 was 
defined as the functional endpoint. A patient reaching 
this score generally has functional deterioration in the 
three separate portions of the scale: habits, personal 
care, and personality. These endpoints were chosen 
from these continuous scales because in our experience 
they correspond to what we consider a "moderate" level 
of dementia. 
Analysis. As an initial estimate of the effectiveness of 
each predictor, chi-square analyses were used to com-
pare the frequency of reaching an endpoint in patients 
with and without a specific sign at their first visit. 
However, this analysis does not reflect the length of 
time patients were followed, and cannot yield informa-
tion about the distribution of time to reach an endpoint. 
To evaluate these issues, the Kaplan-Meier product 
limit technique15 was used. This maximum-likelihood 
nonparametric estimation procedure generates life ta-
bles that describe the probability of patients reaching 
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an endpoint as a function of duration of illness. It takes 
into account the fact that some patients do not reach 
the endpoints during the study period. 
For the purposes of this analysis, patients were fol-
lowed either (1) until they reached each endpoint, or (2) 
until their last visit. Those patients not reaching an 
endpoint by their last visit were withdrawn at the time 
of their last visit. No patient died before reaching an 
endpoint. Some patients had reached one of the study 
endpoints before their first visit. They were excluded 
from the life table analyses since it is not clear whether 
the clinical signs were present prior to reaching the 
endpoint, and therefore these patients are not in-
formative for the evaluation of predictive value. 
"Survival" curves were drawn from life table data to 
represent the probability of reaching an endpoint as 
duration of illness progresses. For comparison, curves 
for each endpoint were plotted simultaneously for pa-
tients with and without each clinical symptom. 
Results. Distribution of clinical signs at first visit. At 
the first visit, 24 (37%) of the patients had extra-
pyramidal signs. Of these, four were classified as "drug-
induced." In none of these patients was the presence of 
these signs suggestive of Parkinson's disease. Psycho-
sis, consisting primarily of delusions, was present in 17 
(27%) of the patients. Myoclonus was noted in five 
(7.8%). Some patients developed extrapyramidal signs, 
psychosis, or myoclonus after their first visit. They were 
classified as being symptom-free at the first visit. Since 
the number of patients with myoclonus at the first visit 
was too small for meaningful application of the epi-
demiologic techniques employed in this study, the pre-
dictive utility of this clinical sign was not investigated. 
However, three patients from this group have died and 
Alzheimer's disease was confirmed and reported.16 
Duration of illness was comparable in patients with 
and without extrapyramidal signs, psychosis, or myo-
clonus but, as reported previously, mMMS scores were 
poorer in patients with these clinical signs and BDRS 
was poorer in the patients with extrapyramidal signs 
(table). 
Distribution of patients reaching endpoints. Twenty 
patients reached the cognitive endpoint and 6 the func-
tional endpoint by the first visit. The distribution of 
patients who had reached endpoints by their first visit 
did not differ in patients with and without extra-
pyramidal signs or with and without psychosis. 
Eighteen of the 20 patients with extrapyramidal 
signs at first visit reached the cognitive endpoint, 
whereas only 22 of 41 patients without these signs 
reached this point. Similarly, 16 of the 20 patients with 
these signs reached the functional endpoint as com-
pared with 22 of the 41 without them. Chi-square analy-
ses suggested that patients who reached the endpoints 
were more likely to have had extrapyramidal signs at 
entry (chi-square ~ 7.91, p < 0.005 and chi-square ~ 
3.97 ,p < 0.05, respectively). In patients with psychosis, 
14 of 20 reached the cognitive endpoint compared with 
27 of 46 without psychosis at first visit (chi-square ~ 
3.06, p < 0.09). Thirteen of 17 patients with psychosis 
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Figure 1. Probability of patients with and without 
extrapyramidal signs at their first visit surviving over time 
without reaching the endpoint of mMMS < 20. Time is 
expressed in duration of illness from estimated date of 
onset 
patients without psychosis (chi-square = 1.33, ns). 
Life table analyses. Extrapyramidal signs. The sur-
vivorship curves in figure 1 represent the probability of 
reaching an mMMS score ofless than 20 as a function of 
duration of illness. Compared with other patients, those 
with extrapyramidal signs at first visit were likely to 
reach this endpoint sooner. Patients with drug-induced 
extrapyramidal signs were excluded from these analy-
ses, but similar results were obtained when these pa-
tients were included in the extrapyramidal group. 
Unlike the results seen with the mMMS endpoint, 
there were no differences between the extrapyramidal 
and non-extrapyramidal groups for reaching the end-
point of BDRS > 15; the survivorship curves virtually 
overlap (figure 2). The median time to this endpoint in 
patients with and without extrapyramidal signs was 5.5 
and 5.8 years, respectively. 
Psychosis. Similar analyses were used to compare 
the duration of illness at which endpoints were reached 
in patients with and without psychosis. Figures 3 and 4 
demonstrate that, compared with patients without psy-
chosis, psychotic patients reached the cognitive end-
point but not the functional endpoint earlier in the 
course of the illness. 
Additional life table analyses. Four of the patients 
with psychosis were receiving antipsychotics for their 
symptoms; four patients without psychosis were also 
receiving these medications for other reasons. These 
medications might influence mMMS or BDRS scores, 
but life tables were similar if patients taking these medi-
cations were excluded from the analyses. 
In order to evaluate the possible contribution of myo-
clonus to the present findings, life tables were recalcu-
lated excluding all patients with myoclonus. Results 
were unchanged. 
Similarly, we evaluated the independent predictive 
value of extrapyramidal signs and psychosis. Life tables 
were recalculated to compare (1) patients with and 
without extrapyramidal signs, with no patients in ei-
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Figure 2. Probability of patients with and without 
extrapyramidal signs at their first visit surviving over time 
without reaching the endpoint of BDRS > 15. Time is 
expressed in duration of illness from estimated date of 
onset. 
without psychosis, with no patients manifesting extra-
pyramidal signs. Results were unchanged. 
Additional analyses were done to evaluate whether 
patients with extrapyramidal signs or psychosis 
reached the endpoints more quickly because they had 
poorer scores on the mMMS and BD RS at the first 
visit. Patients were stratified into groups above and 
below the mean mMMS or BD RS scores at first visit. 
Survivorship curves were then redrawn for these strat-
ified groups. The results were again unchanged, indicat-
ing that poor initial performance did not influence the 
life table results. 
Discussion. Our data suggest that the presence of ex-
trapyramidal signs or psychosis early in the disease may 
predict more rapid intellectual decline. 
Life-table methodology is a powerful way to evaluate 
this type of data because it includes patients in the 
analysis for only the time in which they were studied. 
The survivorship curves are descriptive but suggest the 
robust predictive power of the clinical signs, particu-
larly for the cognitive endpoint. These curves suggest 
that the time for reaching the cognitive endpoint is 
earlier in patients with extrapyramidal signs or psycho-
sis. 
While the survivorship curves suggest that patients 
with extrapyramidal signs or psychotic symptoms 
reach our endpoints more quickly, the curves do not 
differ significantly. Statistical power was limited by the 
relatively small number of patients. Other aspects of the 
data collection were also not optimal. Duration of ill-
ness at first visit and the interval between examinations 
varied between patients. In addition, time from onset of 
symptoms to first visit varied, and endpoints had some-
times been reached before the first visit. The data are 
therefore best analyzed descriptively and used to gener-
ate testable hypotheses. 
The predictors were more useful for the cognitive 
than the functional endpoint. Both endpoints were de-
signed to capture non-overlapping behavioral domains, 
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Figure 3. Probability of patients with and without 
symptoms of psychosis at their first visit surviving over time 
without reaching the endpoint of mMMS < 20. Time is 
expressed in duration of illness from estimated date of 
onset. 
and the predictors could simply have been more useful 
for one of them. However, it is also possible that the 
cutoff score we chose was not meaningful or optimally 
defined. We have shown that there is a relatively steady 
increase in BDRS scores over time,1 so this explanation 
seems unlikely; all patients will eventually reach any 
particular level of functional disability. Still, our cutoff 
point might reflect a degree of disability that is too 
extreme to be useful in delineating the utility of poten-
tial predictors. It is also possible that the BDRS is not 
sensitive or specific enough to capture the range of 
functional changes necessary to demonstrate dif-
ferences between disease subgroups. 
Endpoints are difficult to define since they are often 
dependent on multiple factors. For example, admission 
to a nursing home might appear to be a suitable end-
point for clinical prediction, but the severity of a pa-
tient's dementia is only one factor used to determine 
whether a patient is admitted into such a facility. End-
points must be carefully defined; they must be distinct 
from diagnostic criteria and from the predictors." 
Recently, postmortem studies of patients who had 
had pAD indicated that coincident neuropathologic 
changes of Alzheimer's disease and Parkinson's disease, 
including degeneration in the substantia nigra and 
Lewy bodies, may exist.18 While none of the patients in 
that study or in two previous ones1" had Parkinson's 
disease, it is likely that the noted extrapyramidal signs 
are symptomatic of a more diffuse degenerative process. 
Psychosis at the first visit is also associated with a 
greater probability of reaching the cognitive endpoint 
earlier. We reported these symptoms to be more com-
mon in patients with extrapyramidal signs or myo-
clonus, 1 so it is not clear to what extent they constitute 
separate clinical predictors. However, psychosis and 
extrapyramidal signs were predictive when patients 
who had both clinical signs were excluded from analysis, 
which suggests that each clinical sign has unique pre-
dictive value. 
Although there were too few patients with myo-
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Figure 4. Probability of patients with and without 
symptoms of psychosis at their first visit surviving over time 
without reaching the endpoint of BDRS > 15. Time is 
expressed in duration of illness from estimated date of 
onset. 
clonus at the first visit to include that symptom in these 
analyses, this symptom is associated with a more ag-
gressive disease course.1 An association has been ob-
served between autosomal dominant Alzheimer's 
disease with myoclonus and "spongy change" in the 
neocortex.16 These patients also had a greater number 
of neurofibrillary tangles, suggesting that the presence 
of myoclonus may indicate an aggressive form of Alz-
heimer's disease. Similar biochemical data regarding 
reduced choline acetyltransferase activity in this sub-
group supports this view .19 
These observations need confirmation and verifica-
tion, but they have practical and biologic importance. 
Our data suggest that, at an individual patient's first 
assessment, a clinician may be able to predict how 
rapidly a certain level of intellectual dysfunction will be 
reached. If confirmed, this would have a significant part 
in the long-term care of the patient and the planning of 
the patient and family. Our data also suggest that vari-
ability of biologic changes in Alzheimer's disease influ-
ence its clinical expression. 
Acknowledgments 
We thank the staff of the Clinical Research Center Outpatient Clinic 
for their assistance in following the patients, and Donald McMahon 
for his assistance with data management. 
References 
1. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the 
Alzheimer type: evidence of subgroups. Neurology 
1985;35:453-461. 
2. Mayeux R, Stern Y, Sano M. Psychosis in patients with dementia 
of the Alzheimer type. Abstract. Ann Neurol 1985;18:144. 
3. Stern Y, Mayeux R. Stability and prognostic value of clinical 
heterogeneity in dementia of the Alzheimer type. Abstract. Neu-
rology !985;35(suppl 1):163. 
4. Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of 
dementia of the Alzheimer type. Neurology 1985;35:1544-1550. 
5. APA. Diagnostic and statistical manual of mental disorders, 3rd 
ed. The American Psychiatric Association, 1980. 
6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of 
Alzheimer's disease: Report of the NIN CDS-AD RDA work group 
under the auspices of the Department of Health and Human 
Services Task Force on Alzheimer's disease. Neurology 
1984;34:939-944. 
7. Hachinski VC, Iliff LD, Zhilka E, et al. Cerebral blood flow in 
dementia. Arch Neurol 1975;32:632-637. 
8. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. 
Analysis of the clinical problems in parkinsonism and the com-
plications of long-term levodopa therapy. Neurology 
1979;29:1253-1260. 
9. Montgomery GK, Reynolds NC, Warren RM. Qualitative assess-
ment of Parkinson's disease: study of reliability and data reduc-
tion with an abbreviated Columbia scale. Clin Neuropharmacol 
1985;8:83-92. 
10. Blessed G, Tomlinson BE, Roth M. The association between 
quantitative measures of dementia and of senile changes in the 
cerebral grey matter of elderly subjects. Br J Psycho! 
1968;225:797-811. 
11. Sano M, Stern Y, Mayeux R, Hartman S, Devanand DP. A stan-
dardized technique for establishing the onset symptoms of proba-
ble Alzheimer's disease. Abstract. J Exp Clin Neuropsychol 
1987;9:65-66. 
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state,'' a 
practical method for grading the cognitive state ofpatient.s for the 
clinician. J Psychiatr Res 1975;12:189-198, 
13. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual 
impairment and Parkinson's disease. Neurology 1981;31:645-650. 
14. Stern Y, Sano M, Paulson J, Mayeux R. Modified mini-mental 
state examination: validity and reliability. Abstract. Neurology 
1987;37(suppl 1):179. 
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete 
observations, Amer Stat Assn J 1958;53:457-481. 
16. Mayeux R, Kupsky W, Duffy P, Familial Alzheimer's disease with 
"spongy change." Abstract. Neurology 1986;36(suppl 1):272. 
17. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction 
rules: applications and methodological standards. N Engl J Med 
1985;313:793-799. 
18. Ditter SM, Mirra SS. Parkinson's disease features in Alzheimer's 
disease: a neuropathologic and clinical study. Abstract. Neurology 
1986;36(suppl 1):225. 
19. Bird TD, Stranahan S, Sumi M, Raskind M. Alzheimer's disease 
and choline acetyltransferase activity in brain tissue from clinical 
and pathological subgroups. Ann Neurol 1983;14:184-193. 
October 1987 NEUROLOGY 37 1653 



